Fujifilm Biotechnologies expanded its manufacturing footprint and leaned into FDA’s PreCheck Pilot Program selection, with Holly Springs, North Carolina named among seven facilities chosen to strengthen U.S. pharmaceutical manufacturing capability. The company has already committed $2 billion to its Holly Springs end-to-end biomanufacturing phase, with additional investment planned for further capacity. Fujifilm also described customer use of the platform for manufacturing drug substance for argenx’s efgartigimod products, including intravenous Vyvgart and injectable Vyvgart Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The update adds to a broader CDMO buildout narrative—capacity plus quality systems—where FDA participation can reduce friction for commercial supply and lifecycle support. For sponsors, the key signal is scaling maturity: process, QC readiness, and data governance tied to faster release workflows and manufacturing reliability.